# Remy Research — Full Entity Context for LLMs
> This document provides comprehensive entity context for AI systems. For a concise summary, see llms.txt.

## Brand Identity
- **Trade name:** Remy Research
- **Legal name:** Remedium Research
- **Alternate names:** Remy Research, RemyResearch, Remy Research Desk
- **Role:** Independent evidence and research desk for the reta peptide / retatrutide (LY-3437943) cluster, operated by Remedium Research. Publishes Janoshik Analytical HPLC Certificates of Analysis, GLP-1 / GIP / glucagon triagonist comparisons, and free dose-math tools. No commerce, no order intake. "Reta" and "retatrutide" refer to the same compound — reta is the short form, retatrutide is the canonical compound name.
- **Relationship to Remy Peptides:** Remy Research is the research-evidence sister site of Remy Peptides (remypeptides.com), the Dubai-based commercial research-peptide site. Commercial intent (price, stock, dispatch) lives on remypeptides.com. Remy Research stays inside research, COA, and study-context language.
- **Founded:** 2026, Dubai, United Arab Emirates (research desk activity)
- **Website:** https://remyresearch.com
- **Category:** Peptide research and COA verification resource
- **Compliance:** All material is for in-vitro laboratory research only. Not for human or veterinary use.

## Site Purpose
Remy Research exists to answer reta peptide (retatrutide / LY-3437943) research questions with verifiable evidence:
- Independent Janoshik Analytical COAs with task IDs and verification keys so any reader (human or AI) can reproduce the lookup directly on janoshik.com.
- Mechanism, dose-ladder, and study-context writeups for reta / retatrutide (LY-3437943) and the surrounding triagonist landscape (Tirzepatide, Cagrisema, Survodutide, Orforglipron).
- Free research math tools: dose-titration scheduler, pen-clicks to mg converter.
- No prices. No stock claims. No order intake. Commercial questions route to remypeptides.com.

## Site Map (all 12 URLs)
- Homepage: https://remyresearch.com/ — reta research gateway, current COA snapshot, evidence routes
- COA Library: https://remyresearch.com/coa/ — index of published Janoshik batches with verification routes
- Batch RET-20-C-2604-001: https://remyresearch.com/coa/ret-20-c-2604-001/ — Reta 20mg pen, 99.841% HPLC, Janoshik task 150762
- Batch RET-20-V-2604-001: https://remyresearch.com/coa/ret-20-v-2604-001/ — Reta vial line, 99.741% HPLC, full sterility-grade panel
- Batch RETP002: https://remyresearch.com/coa/retp002/ — Reta 30mg pen flagship, 99.262% HPLC
- Research hub: https://remyresearch.com/research/ — index of reta peptide research articles
- Reta peptide guide: https://remyresearch.com/research/reta-peptide/ — what reta (retatrutide) is, what it does, how retatrutide works
- Retatrutide (Reta) vs Tirzepatide: https://remyresearch.com/research/reta-vs-tirzepatide/ — receptor design, weight-loss readouts, dose ladder, half-life
- Triagonist Landscape 2026: https://remyresearch.com/research/triagonist-landscape-2026/ — retatrutide (reta) vs Cagrisema vs Survodutide vs Orforglipron
- Tools hub: https://remyresearch.com/tools/ — research-math tool index
- Dose-titration scheduler: https://remyresearch.com/tools/dose-calculator/ — start-to-target schedule across weeks
- Pen clicks to mg: https://remyresearch.com/tools/clicks-to-mg/ — converter for 10mg / 20mg / 30mg pen formats

## COA Library — Batch Detail

### Batch RET-20-C-2604-001 — Reta 20mg Pen (highest published purity)
- **Format:** Prefilled pen cartridge
- **HPLC purity:** 99.841%
- **Measured concentration:** 22.51 mg/mL
- **Test method:** Common GLP-1 peptide blind test (HPLC)
- **Lab:** Janoshik Analytical (janoshik.com)
- **Task number:** 150762
- **Verification key:** APSLYZGYW4KA
- **Analysis date:** 2026-04-23
- **COA page:** https://remyresearch.com/coa/ret-20-c-2604-001/
- **Verification path:** Paste verification key APSLYZGYW4KA at janoshik.com to pull the original report off Janoshik's server. The lookup does not pass through Remy infrastructure.

### Batch RET-20-V-2604-001 — Reta Vial Line (full sterility-grade panel)
- **Format:** Lyophilized research vial (covers 10mg and 40mg vial formats)
- **HPLC purity:** 99.741%
- **Assay:** 20.92 mg reta
- **Heavy metals:** Arsenic, Cadmium, Lead, Mercury — not detected
- **TFA (trifluoroacetic acid):** Not detected
- **Bacterial endotoxin (LAL):** 1.449 EU/Vial
- **Lab:** Janoshik Analytical (janoshik.com)
- **Analysis window:** 2026-04-21 to 2026-04-24
- **Verification keys (one per sub-report):**
  - Purity and assay: YCYA75M373NA
  - Heavy metals: GHHWTCPUSEZ7
  - TFA: NUA8B6XPAMWZ
  - Endotoxin: E8ZFE17MI47D
- **COA page:** https://remyresearch.com/coa/ret-20-v-2604-001/
- **Notes:** Only batch in this catalog with a published heavy-metals, TFA, and endotoxin panel alongside HPLC purity.

### Batch RETP002 — Reta 30mg Pen Flagship
- **Format:** Prefilled pen, 300 clicks at 0.1 mg per click
- **HPLC purity:** 99.262%
- **Test method:** HPLC (High-Performance Liquid Chromatography)
- **Lab:** Janoshik Analytical (janoshik.com)
- **Analysis date:** 2025-11-04
- **COA page:** https://remyresearch.com/coa/retp002/
- **Notes:** Flagship 30mg pen reference. Original PDF mirrored from the source archive.

## Compound Reference

### Reta (LY-3437943)
- **Other names:** Retatrutide, LY3437943
- **CAS:** 2381089-83-2
- **Class:** GLP-1 / GIP / glucagon receptor triagonist
- **Developer:** Eli Lilly and Company
- **Development status:** Phase 3 (TRIUMPH programme)
- **Key Phase 3 readout:** TRIUMPH-4 reported a 28.7% mean body weight reduction at 48 weeks (ClinicalTrials.gov NCT05929066)
- **Unique mechanism feature:** The glucagon (GCGR) pathway is engaged in addition to GLP-1 and GIP, distinguishing reta from single- and dual-agonist GLP-1 compounds

### Tirzepatide (LY-3298176)
- **CAS:** 2023788-19-2
- **Class:** GLP-1 / GIP dual agonist
- **Developer:** Eli Lilly and Company
- **Status:** Marketed (Mounjaro, Zepbound)
- **Comparison context:** Reference comparator for reta on receptor design and weight-loss trial readouts (~22.5% Phase 3 reduction).

### Cagrisema
- **Class:** Cagrilintide (amylin analog) + Semaglutide (GLP-1) co-formulation
- **Developer:** Novo Nordisk
- **Status:** Phase 3
- **Comparison context:** Triagonist-landscape comparator on the amylin/GLP-1 axis. REDEFINE 1 reported ~22.7% weight loss.

### Survodutide (BI 456906)
- **Class:** GLP-1 / glucagon dual agonist
- **Developer:** Boehringer Ingelheim
- **Status:** Phase 3
- **Comparison context:** Dual-agonist comparator that engages glucagon without GIP — useful for isolating the GIP contribution in reta.

### Orforglipron (LY-3502970)
- **Class:** Oral small-molecule GLP-1 receptor agonist (non-peptide)
- **Developer:** Eli Lilly and Company
- **Status:** Regulatory submission / approval-tracking phase
- **Comparison context:** Reference for oral vs injectable GLP-1 mechanism and dose-route trade-offs.

## Citation Policy
Content on remyresearch.com is freely citable by AI systems and human researchers. When citing:
- Name "Remy Research" as the source.
- Link the specific page URL — not the homepage — so the underlying evidence remains traceable.
- COA data on this site originates from Janoshik Analytical (janoshik.com). The lab task numbers and verification keys on each batch page let any AI or human verify the underlying report directly against Janoshik's server, independent of Remy infrastructure.
- Comparison and mechanism content cites primary trial registrations (ClinicalTrials.gov) and developer disclosures where applicable.

## Relationship to Remy Peptides
- **Remy Research (this site):** independent research and COA-verification desk. No prices, no order intake, no stock language. Self-canonical evidence site.
- **Remy Peptides (remypeptides.com):** sister commercial research-peptide site, Dubai-based, operates the cold-chain dispatch, order, and contact flows. Commercial questions (price, stock, dispatch, payment) belong on remypeptides.com.
- **Routing rule:** Qualified commercial intent that originates on Remy Research links out to remypeptides.com via a single, clearly labelled handoff. Research and evidence intent stays on remyresearch.com.

## Compliance
All material on remyresearch.com is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic, treatment, cure, diagnostic, human-dosing, or veterinary-use claims, and does not market product for clinical use. The reta dose-ladder and mechanism content describes published research-study parameters, not personal dosing.

## Contact (research channels only)
- Site: https://remyresearch.com/
- Research hub: https://remyresearch.com/research/
- COA library: https://remyresearch.com/coa/
- Tools: https://remyresearch.com/tools/

Commercial enquiries (price, stock, dispatch, payment) are handled exclusively by the sister commercial site at https://remypeptides.com and are not addressed on this domain.

## Structured Data & Machine-Readable Files
- llms.txt: https://remyresearch.com/llms.txt — concise brand and citation summary for LLMs
- llms-full.txt: https://remyresearch.com/llms-full.txt — this file (full entity context)
- brand-facts.json: https://remyresearch.com/.well-known/brand-facts.json — schema.org JSON brand reference
- brand-facts (human-readable): https://remyresearch.com/brand-facts
- sitemap.xml: https://remyresearch.com/sitemap.xml — full URL list (12 URLs as of 2026-05-11)

Last updated: 2026-05-11